Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus

New treatment options constitute unmet needs for patients diagnosed with systemic lupus erythematosus (SLE). Inhibition of the mammalian target of rapamycin (mTOR) pathway by sirolimus, a drug approved and in clinical use to prevent transplant rejection, has shown promising effects in lupus animal m...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, Per, Wallin, Philip, Sjöwall, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372521/
https://www.ncbi.nlm.nih.gov/pubmed/30787878
http://dx.doi.org/10.3389/fphar.2019.00082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372521/
https://www.ncbi.nlm.nih.gov/pubmed/30787878
http://dx.doi.org/10.3389/fphar.2019.00082

Ejemplares similares